Skip directly to site content Skip directly to search


Español  Other Languages


Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People
 Search

		Submit


Tuberculosis (TB)








Aggregate Reports for Tuberculosis Program Evaluation (ARPE)							Updated February 16, 2023
																	Related Pages
										Return to Main Menu*This webpage includes information about the Follow-Up & Treatment of Contacts of Tuberculosis Patients Form and the Targeted Testing and Treatment for Latent Tuberculosis Infection Form.*Strategies for tuberculosis (TB) prevention include contact investigations [PDF – 4 MB], targeted testing, and treatment of latent tuberculosis infection (LTBI). The Aggregate Reports for Tuberculosis Program Evaluation (ARPE) provide national summaries of these activities carried out by TB programs in the U.S. TB programs submit these data through the National Tuberculosis Indicators Project (NTIP), a web-based monitoring tool that allows TB programs to monitor their performance toward meeting National TB Program Objectives and Performance Targets.
Contact investigation and targeted testing data are submitted to CDC using two separate ARPE forms: 1) Follow-Up & Treatment of Contacts of Tuberculosis Patients Form, and, 2) Targeted Testing and Treatment for Latent Tuberculosis Infection Form.ARPE Follow-Up & Treatment of Contacts of Tuberculosis Patients FormThe Follow-Up & Treatment of Contacts of Tuberculosis Patients form provides an annual summary about identifying and evaluating contacts to TB cases and treating the contacts who test positive for latent TB infection (LTBI) using the following 3 categories of TB cases:
**Sputum Smear Positive:** are defined as cases that meet all of the following criteria: 1) inclusion in the overall surveillance count, 2) a disease site in the respiratory system including the airways, and 3) a positive acid-fast bacilli (AFB) sputum-smear result, whether or not any culture result is positive.
**Sputum Smear Negative Culture Positive:** are defined as cases that meet all of the following criteria: 1) inclusion in the overall surveillance count, 2) a disease site in the respiratory system including the airways, 3) negative AFB sputum smear results, and 4) sputum culture result positive for *Mycobacterium tuberculosis*.
**Other:** This category includes contact investigations that were done because of any circumstances not included in the other two categories. Example: Associate-contact or source-case investigations done because of TB in a child. The number of contacts is counted, but the number of cases for investigation is not.
Funded TB programs are required to submit a completed ARPE Follow-Up & Treatment of Contacts of Tuberculosis Patients form to CDC each year (due by March 31st). Contact investigation data are summarized annually in the Contact Investigations Report (ARPE Data) and the State and City TB Report.
A PDF copy of the form and updated guidance and brief instructions (updated in 2020; form 0920-0457; expiration date 01/31/2026) are available at the link below:
ARPE Follow-Up Treatment of Contacts of Tuberculosis Patients Form & Updated GuidanceOn This Page
			Contact Follow-Up FormTargeted Testing FormSubmissionRelated LinksContact Follow-Up Form Data ItemsRequired Data ItemsNumber of TB cases for investigation
Number of cases with no contacts
Number of contacts
Number of contacts evaluated
Number of contacts diagnosed with TB disease
Number of contacts diagnosed with LTBI
Number of contacts with LTBI who started treatment
Number of contacts with LTBI who started and then completed treatment
Number of contacts who did not complete LTBI treatment due to development of active TB
Number of contacts who did not complete LTBI treatment due to adverse effects of medicine
Number of contacts who did not complete LTBI treatment because they chose to stop treatment
Number of contacts who did not complete LTBI treatment because they were lost to follow-up
Number of contacts who did not complete LTBI treatment because they moved (follow-up was unknown)
Number of contacts who did not complete LTBI treatment due to death
Number of contacts who did not complete LTBI treatment due to health care provider decision to stopOptional Data ItemsNumber of U.S.-born contacts
Number of non-U.S.–born contacts
Number of contacts evaluated by tuberculin skin test (TST)
Number of contacts evaluated by interferon-gamma release assay (IGRA)
Number of contacts with LTBI who started a prescribed treatment regimen of once-weekly isoniazid-rifapentine for 3 months (3HP)
Number of contacts with LTBI who started a prescribed treatment regimen of daily rifampin for 4 months (RIF 4 months; also known as 4R)
Number of contacts with LTBI who started a prescribed treatment regimen of daily isoniazid-rifampin for 3 months (3HR)
Number of contacts with LTBI who started a prescribed treatment regimen of isoniazid for 6 months (INH 6 months; also known as 6H)
Number of contacts with LTBI who started a prescribed treatment regimen of isoniazid for 9 months (INH 9 months; also known as 9H)
Number of contacts with LTBI who started treatment other than the drug regimens previously listed
Number of contacts with LTBI who started treatment without the drug regimen being documented
Number of patients who completed 3HP treatment
Number of patients who completed 4R/RIF (4 months) treatment
Number of patients who completed 3HR treatment
Number of patients who completed 6H/INH (6 months) treatment
Number of patients who completed 9H/INH (9 months) treatment
Number of patients who completed treatment other than the drug regimens listed previously
Number patients who completed treatment without the drug regimen being documentedARPE Targeted Testing and Treatment for Latent Tuberculosis Infection FormThe Targeted Testing (TT) Form is used to submit annual summaries about targeted testing conducted among populations with a high prevalence rate of LTBI or a high risk of progression to TB from LTBI. TB programs can submit targeted testing data for persons using the following 3 categories:
**Targeted Testing Project Category:** Targeted testing projects for groups done at sites outside the health department, as determined for convenience or by the needs of the groups being tested.
**Targeted Testing Individual Category:** Targeted testing done one person at a time or by group but outside of testing projects, when testing is in accordance with national, state, or local guidelines for selecting persons who are at risk for TB and who are expected to be candidates for treatment if they have LTBI.
**Targeted Testing Administrative Category:** Targeted testing done when the testing is a low public health priority because the tested persons or groups are not at risk for TB and might not even be candidates for LTBI.The TT form includes submission of data by Medical or Population risk. Every person who is listed with LTBI should be classified as either Medical risk or Population risk, but not both. If a person can be counted in both categories, they should only be listed as Medical risk. If a person has no known medical risks, they should be counted under Population risk.
Funded TB programs with high TB incidence (defined as >=150 cases per year) in their jurisdiction are required to submit targeted testing data for each calendar year (also known as a cohort year)*.*Regardless of each jurisdiction’s level of TB incidence, all TB programs are encouraged to submit this information to CDC each year.
A PDF copy of this form and updated guidance and instructions are available at the link below:
The ARPE Targeted Testing and Treatment for Latent Tuberculosis Infection Form & Updated GuidanceTargeted Testing Form Data ItemsRequired Data ItemsNumber of persons sought, enlisted, or registered for targeted testing projects
Number of persons evaluated
Number of persons diagnosed with TB disease
Number of persons diagnosed with LTBI
Number of persons with a medical risk who testing positive for LTBI
Number of persons with a population risk who testing positive for LTBI
Number of persons with a medical risk who are candidates for LTBI treatment
Number of persons with a population risk who are candidates for LTBI treatment
Number persons with LTBI with a medical risk who started treatment
Number of persons with LTBI with a population risk who started treatment
Number of persons with LTBI with a medical risk who started and then completed treatment
Number of persons with LTBI with a population risk who started and then completed treatment
Number of patients who did not complete treatment due to active TB developed
Number of patients who did not complete treatment due to adverse effect of medicine
Number of patients who did not complete treatment due to contact chose to stop
Number of patients who did not complete treatment due to contact lost to follow-up
Number of patients who did not complete treatment due to contact moved (follow-up unknown)
Number of patients who did not complete treatment due to death
Number of patients who did not complete treatment due to health care provider decision to stopOptional Data ItemsNumber of U.S.-born persons
Number of non-U.S.–born persons
Number of persons evaluated by TST (persons who were evaluated by both TST and IGRA can be counted in both data fields)
Number of persons evaluated by IGRA (persons who were evaluated by both TST and IGRA can be counted in both data fields)
Number of persons with a medical risk who started a prescribed treatment regimen of once-weekly isoniazid-rifapentine for 3 months (3HP)
Number of persons with a population risk who started a prescribed treatment regimen of once-weekly isoniazid-rifapentine for 3 months (3HP)
Number of persons with a medical risk who started a prescribed treatment regimen of daily rifampin for 4 months (RIF 4 months; also known as 4R)
Number of persons with a population risk who started a prescribed treatment regimen of daily rifampin for 4 months (RIF 4 months; also known as 4R)
Number of persons with a medical risk who started a prescribed treatment regimen of daily isoniazid-rifampin for 3 months (3HR)
Number of persons with a population risk who started a prescribed treatment regimen of daily isoniazid-rifampin for 3 months (3HR)
Number of persons with a medical risk who started a prescribed treatment regimen of isoniazid for 6 months (INH 6 months; also known as 6H)
Number of persons with a population risk who started a prescribed treatment regimen of isoniazid for 6 months (INH 6 months; also known as 6H)
Number of persons with a medical risk who started a prescribed treatment regimen of isoniazid for 9 months (INH 9 months; also known as 9H)
Number of persons with a population risk who started a prescribed treatment regimen of isoniazid for 9 months (INH 9 months; also known as 9H)
Number of persons with a medical risk who started treatment other than the drug regimens listed previously
Number of persons with a population risk who started treatment other than the drug regimens listed previously
Number of persons with a medical risk who started treatment without the drug regimen being documented
Number of persons with a population risk who started treatment without the drug regimen being documented
Number of patients with a medical risk who completed 3HP treatment
Number of patients with a population risk who completed 3HP treatment
Number of patients with a medical risk who completed 4R/RIF (4 months) treatment
Number of patients with a population risk who completed 4R/RIF (4 months) treatment
Number of patients with a medical risk who completed 3HR treatment
Number of patients with a population risk who completed 3HR treatment
Number of patients with a medical risk who completed 6H/INH (6 months) treatment
Number of patients with a population risk who completed 6H/INH (6 months) treatment
Number of patients with a medical risk who completed 9H/INH (9 months) treatment
Number of patients with a population risk who completed 9H/INH (9 months) treatment
Number of patients with a medical risk who completed treatment other than the drug regimens listed previously
Number of patients with a population risk who completed treatment other than the drug regimens listed previously
Number of patients with a medical risk who completed treatment without the drug regimen being documented
Number of patients with a population risk who completed treatment without the drug regimen being documented*The Targeted Testing Form also includes data items for persons referred to by the health department for testing because of possible LTBI. All data items in Part III of the form are optional for submission.*Optional Data Items - Part IIINumber of persons with a medical risk referred for testing
Number of persons with a population risk referred for testing
Number of U.S.–born persons with a medical risk referred for testing
Number of U.S.–born persons with a population risk referred for testing
Number of non-U.S.–born persons with a medical risk referred for testing
Number of non-U.S.–born persons with a population risk referred for testing
Number of persons with a medical risk who were evaluated
Number of persons with a population risk who were evaluated
Number of persons with a medical risk who were evaluated by TST
Number of persons with a population risk who were evaluated by TST
Number of persons with a medical risk who were evaluated by IGRA
Number of persons with a population risk who were evaluated by IGRA
Number of persons with a medical risk who were diagnosed with TB disease
Number of persons with a population risk who were diagnosed with TB disease
Number of persons with a medical risk who were diagnosed with LTBI
Number of persons with a population risk who were diagnosed with LTBI
Number of persons with a medical risk who are candidates for LTBI treatment
Number of persons with a population risk who are candidates for LTBI treatment
Number of persons with LTBI with a medical risk who started treatment
Number of persons with LTBI with a population risk who started treatment
Number of persons with a medical risk who started 3HP treatment
Number of persons with a population risk who started 3HP treatment
Number of persons with a medical risk who started 4R/RIF (4 months) treatment
Number of persons with a population risk who started 4R/RIF (4 months) treatment
Number of persons with a medical risk who started 3HR treatment
Number of persons with a population risk who started 3HR treatment
Number of persons with a medical risk who started 6H/INH (6 months) treatment
Number of persons with a population risk who started 6H/INH (6 months) treatment
Number of persons with a medical risk who started 9H/INH (9 months) treatment
Number of persons with a population risk who started 9H/INH (9 months) treatment
Number of persons with a medical risk who started other than the regimens listed previously
Number of persons with a population risk who started other than the regimens listed previously
Number of persons with a medical risk who started treatment without a drug regimen being documented
Number of persons with a population risk who started treatment without a drug regimen being documented
Number of persons with LTBI treatment with a medical risk who started and then completed treatment
Number of persons with LTBI treatment with a population risk who started and then completed treatment
Number of patients with a medical risk who completed 3HP treatment
Number of patients with a population risk who completed 3HP treatment
Number of patients with a medical risk who completed 4R/RIF (4 months) treatment
Number of patients with a population risk who completed 4R/RIF (4 months) treatment
Number of patients with a medical risk who completed 3HR treatment
Number of patients with a population risk who completed 3HR treatment
Number of patients with a medical risk who completed 6H/INH (6 months) treatment
Number of patients with a population risk who completed 6H/INH (6 months) treatment
Number of patients with a medical risk who completed 9H/INH (9 months) treatment
Number of patients with a population risk who completed 9H/INH (9 months) treatment
Number of patients with a medical risk who completed other treatment
Number of patients with a population risk who completed other treatment
Number of patients with a medical risk who completed unknown treatment
Number of patients with a population risk who completed unknown treatment
Number of patients with a medical risk who did not complete treatment due to active TB developed
Number of patients with a population risk who did not complete treatment due to active TB developed
Number of patients with a medical risk who did not complete treatment due to adverse effect of medicine
Number of patients with a population risk who did not complete treatment due to adverse effect of medicine
Number of patients with a medical risk who did not complete treatment due to contact chose to stop
Number of patients with a population risk who did not complete treatment due to contact chose to stop
Number of patients with a medical risk who did not complete treatment due to contact lost to follow-up
Number of patients with a population risk who did not complete treatment due to contact lost to follow-up
Number of patients with a medical risk who did not complete treatment due to contact moved (follow-up unknown)
Number of patients with a population risk who did not complete treatment due to contact moved (follow-up unknown)
Number of patients with a medical risk who did not complete treatment due to death
Number of patients with a population risk who did not complete treatment due to death
Number of patients with a medical risk who did not complete treatment due to health care provider decision to stop
Number of patients with a population risk who did not complete treatment due to health care provider decision to stopWhen and How to Submit ARPE DataARPE contact follow-up and targeted testing data are submitted using the National Tuberculosis Indicators Project (NTIP) web-based tool. Only state and local TB program staff who are designated by the State Surveillance Administrator have been granted access to NTIP. Staff who need access to NTIP should contact their State Surveillance Administrator or the CDC’s DTBE Technical Support Helpdesk via DTBESupport@cdc.gov for assistance.
A preliminary report should be entered into NTIP by March 31 after the cohort year. The final report, including the completion of therapy data, are due for submission to CDC no later than the next March 31st (one year after submission of the preliminary report). For example, by March 31st, 2022, the preliminary report for cohort year 2021 and the final report for cohort year 2020 are due for submission to CDC.
More information about how to search, submit, upload, or export ARPE forms are listed in the NTIP Online Help Webpage (this webpage is only accessible to TB Program staff who have been granted access to NTIP).Related LinksAggregate Reports for Tuberculosis Program Evaluation Training Manual
ARPE Follow-Up Treatment of Contacts of Tuberculosis Patients Form & Updated Guidance
ARPE Targeted Testing and Treatment for Latent Tuberculosis Infection Form & Updated Guidance
							
					
							Last Reviewed:  February 16, 2023						Source: 	Division of Tuberculosis Elimination, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention
					Facebook
        Twitter
        LinkedIn
        Syndicate homeTuberculosisBasic TB Factsplus iconHow TB SpreadsLatent TB Infection and TB DiseaseSigns & SymptomsTB Risk FactorsExposure to TBTB PreventionVaccinesTB & HIV CoinfectionTB and DiabetesTB TermsPersonal StoriesTesting & Diagnosisplus iconWho Should be TestedTesting for TB InfectionTesting in BCG-Vaccinated PersonsTB Screening and Testing of Health Care PersonnelTesting During PregnancyDiagnosing latent TB infection and TB diseaseTreatmentplus iconDeciding When to Treat Latent TB InfectionTreatment Regimens for Latent TB Infection (LTBI)Treatment for TB DiseaseAdverse EventsTB Treatment of Persons Living with HIVTB Treatment and PregnancyTB Treatment for ChildrenFrequently Asked QuestionsDrug-Resistant TBResearchplus iconTB Epidemiologic Studies Consortiumplus iconResearch ProjectsPublicationsTB Trials Consortiumplus iconStudy DescriptionsBackgroundBehavioral & Social Science ResearchHealth Care Settingsplus iconTB Infection Control in Health Care SettingsResources for TB Screening and Testing of Health Care Personnelplus iconFrequently Asked QuestionsTB in Specific Populationsplus iconHealth DisparitiesAsian PersonsBlack or African American PersonsHispanic or Latino PersonsChildrenPregnancyCorrectional FacilitiesPeople Experiencing HomelessnessInternational TravelersLaboratory Informationplus iconDrug Susceptibility TestingFalse-Positive Investigation ToolkitInterim Laboratory Biosafety Guidance for XDR  tuberculosis strainsModel Performance Evaluation Program (MPEP)Rapid Molecular Testing to Detect Drug-Resistant TB in the USplus iconExecutive SummaryIntroductionBackground on Tests for Molecular Detection of DRGeneral Considerations and Principles for a Molecular DR Testing ServicePossible Scenarios and Scope of Testing for a Molecular DR Testing ServiceResearch NeedsGeneral Recommendations of the Expert PanelCommunication Plan for the ReportRecommendationsReferencesPanel Members and CDC ParticipantsAppendix 1Appendix 2Appendix 3The Uses of Nucleic Acid Amplification Tests for the Diagnosis of TBplus iconGeneral ConsiderationsGeneral Recommendations of the Expert PanelRecommendations to ACET, CDC, DTBEData & Statisticsplus iconTB Incidence in the United StatesReported TB in the US, 2022 Surveillance Reportplus iconNational DataReporting Area DataRisk FactorsDemographicsTB Treatment and Case OutcomesDrug-Resistant TBMolecular SurveillanceTuberculosis in the United States, 2022 (Slide Set)Archived Surveillance Reports and Slide Sets2021 State and City ReportArchived State and City ReportsProfessional Resources & Toolsplus iconTools for Healthcare ProvidersResources for TB Programsplus iconStrengthening Civil Surgeons’ Capacity to Improve LTBI Surveillance and Outcomes Among Status AdjustersNotice of Funding Opportunity (NOFO)Program EvaluationTB Centers of ExcellenceTB Elimination AllianceTB Genotypingplus iconConventional TB GenotypingWhole Genome SequencingTB GIMSAnalytic ToolsLatent Tuberculosis Infection ResourcesPublications & Productsplus iconPatient and Public MaterialsFact SheetsGuidelinesplus iconControl & EliminationDrug-Resistant TBInfection Control & PreventionLaboratory & GenotypingTB & HIVTB in Specific PopulationsTesting & DiagnosisTreatmentVaccines & ImmunizationsArchived TB GuidelinesGuides & Toolkitsplus iconAggregate ReportsCDC TB Surveillance TrainingCore CurriculumEffective TB Interviewing for Contact InvestigationEthnographic GuidesFalse-Positive Investigation ToolkitForging Partnerships to Eliminate TuberculosisGuide to Application of GenotypingLTBI: A Guide for Primary Health Care ProvidersMantoux Tuberculin Skin Testing ProductsReport of Verified Case of Tuberculosis (RVCT)Self-Study ModulesTB Contact Investigation Interviewing Skills CourseTB eDOT ToolkitUnderstanding the TB Cohort Review ProcessNewslettersplus iconTB Notes, No. 4, 2023TB Notes, No. 3, 2023TB Notes. No. 2, 2023TB Notes. No. 1, 2023TB Notes, No. 4, 2022TB Notes, No. 3, 2022TB Notes, No. 2, 2022TB Notes, No. 1, 2022TB Notes, No. 4, 2021TB Notes, No. 3, 2021TB Notes, No. 2, 2021TB Notes, No. 1, 2021Pamphlets, Brochures, Bookletsplus iconQuestions and AnswersPatient Education SeriesTuberculosis - Get the FactsTuberculosis - The Connection between TB and HIV12-Dose Regimen for Latent TB Infection-Patient Education BrochurePostersplus iconMantoux Tuberculin Skin Test Wall ChartWorld TB DayThink TBStop TBTake on TBReports & Articlesplus iconDTBE Authored Journal ArticlesTuberculosis Laboratory Aggregate ReportsSlide Setsplus iconIntroduction to TuberculosisEpidemiology of Tuberculosis Among Non-U.S.​–Born Persons in the United States, 1993–2016Self-Study Modules on Tuberculosis, 1-5 Slide SetsThe Tuberculosis (TB) in Correctional Settingsplus iconFacilitator GuideIntroduction to TB GenotypingEpidemiology of Tuberculosis in Correctional Facilities, United States, 1993-2017Prevention and Control of Tuberculosis in Correctional and Detention FacilitiesGuidelines for Preventing the Transmission of M. TB in Health care SettingsInvestigation of Contacts of Persons with Infectious TBEpidemiology of Pediatric Tuberculosis in the United StatesTargeted Tuberculosis Testing and Treatment of Latent Tuberculosis InfectionElectronic Tools & ResourcesWeb-Based Courses & Webinarsplus iconTB 101 for Health Care WorkersContent SyndicationInfographicsplus iconSocial Media GraphicsCustomizable Take on TB Infographic with InstructionsEventsWorld TB Dayplus iconU.S. TB ChampionsHistoryFeaturesplus iconTB Risk FactorsTreating Latent TB Infection with Short-Course RegimensWorld Tuberculosis (TB) Day 2021World Tuberculosis (TB) Day 2020Linksplus iconState TB Control OfficesAbout Usplus iconMission Statement and Activitiesplus iconDTBE Strategic PlanNational TB Program ObjectivesOrganization ChartAdvisory Groupsplus iconFederal TB Task Force


About CDC
					Contact Us
					800-232-4636
 Facebook Twitter Instagram LinkedIn Youtube Pinterest Snapchat
 CONTACT CDC
				Contact Us
							Call 800-232-4636
							Email Us
			ABOUT CDC
				About CDC
							Jobs
							Funding
			POLICIES
				Accessibility
							External Links
							Privacy
							Policies
							No Fear Act
							FOIA
							OIG
							Nondiscrimination
							Vulnerability Disclosure Policy
			CONNECT WITH US
				Facebook
								Twitter
								Instagram
								LinkedIn
							Youtube
								Pinterest
								Snapchat
								Email
			LANGUAGES
				Español
							繁體中文
							Tiếng Việt
							한국어
							Tagalog
							Русский
							العربية
							Kreyòl Ayisyen
							Français
							Polski
							Português
							Italiano
							Deutsch
							日本語
							فارسی
							English


U.S. Department of Health & Human Services
			Accessibility
			External Links
			Privacy
			Policies
			No Fear Act
			FOIA
			Nondiscrimination
			OIG
			Vulnerability Disclosure Policy
			USA.gov


Exit Notification / Disclaimer Policy Close
 Links with this icon  indicate that you are leaving the CDC website. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
				Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
				You will be subject to the destination website's privacy policy when you follow the link.
				CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. Website Disclaimers
 Cancel Continue